Ensign Peak Advisors
CRNX

Ensign Peak Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

Ensign Peak Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.51M Sell
67,004
-8,420
-11% -$313K ﹤0.01% 691
2026
Q1 		$2.74M Sell
75,424
-200,192
-73% -$8.94M 0.01% 650
2025
Q4 		$12.8M Sell
275,616
-19,392
-7% -$863K 0.02% 359
2025
Q3 		$12.3M Sell
295,008
-20,556
-7% -$657K 0.02% 411
2025
Q2 		$9.08M Sell
315,564
-199,245
-39% -$6.15M 0.02% 500
2025
Q1 		$17.3M Buy
514,809
+12,119
+2% +$453K 0.03% 330
2024
Q4 		$25.7M Sell
502,690
-114,147
-19% -$6.39M 0.05% 281
2024
Q3 		$31.5M Buy
616,837
+610
+0.1% +$31.5K 0.06% 244
2024
Q2 		$27.6M Sell
616,227
-5,280
-0.8% -$244K 0.05% 256
2024
Q1 		$29.1M Buy
621,507
+185,822
+43% +$7.27M 0.05% 257
2023
Q4 		$15.5M Buy
435,685
+51,000
+13% +$1.56M 0.03% 339
2023
Q3 		$11.4M Buy
384,685
+114,416
+42% +$2.36M 0.02% 357
2023
Q2 		$4.87M Hold
270,269
– – 0.01% 595
2023
Q1 		$4.34M Hold
270,269
– – 0.01% 609
2022
Q4 		$4.95M Buy
270,269
+177,945
+193% +$3.14M 0.01% 559
2022
Q3 		$1.81M Buy
92,324
+7,700
+9% +$157K ﹤0.01% 822
2022
Q2 		$1.58M Buy
84,624
+23,663
+39% +$472K ﹤0.01% 906
2022
Q1 		$1.34M Buy
60,961
+26,760
+78% +$542K ﹤0.01% 1048
2021
Q4 		$971K Buy
34,201
+13,080
+62% +$322K ﹤0.01% 1305
2021
Q3 		$445K Buy
+21,121
New +$442K ﹤0.01% 1646
2020
Q2 		– Sell
-1,104
Closed -$16K – 1680
2020
Q1 		$16K Sell
1,104
-1,104
-50% -$22.6K ﹤0.01% 1619
2019
Q4 		$55K Buy
+2,208
New +$42K ﹤0.01% 1651

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ensign Peak Advisors's CRNX Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Crinetics Pharmaceuticals (CRNX) stake by 11% in Q2 2026, selling an estimated $313K and leaving 67,004 shares worth $2.51M. The position accounts for ﹤0.01% of the portfolio, ranked #691.

Ensign Peak Advisors first reported a position in CRNX in Q4 2019 and has held it in 22 quarters since. The position peaked at $31.5M in Q3 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Ensign Peak Advisors held 67,004 shares of Crinetics Pharmaceuticals worth $2.51M as of Q2 2026.
  • Ensign Peak Advisors sold 8,420 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $313K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #691 holding.
  • Ensign Peak Advisors first reported a position in Crinetics Pharmaceuticals in Q4 2019 and has held it in 22 quarters since.
  • Ensign Peak Advisors's Crinetics Pharmaceuticals position peaked at $31.5M in Q3 2024.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.